Replicel Life Sciences Inc REPCF

Primary Symbol: V.RP

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > RepliCel Life signs LOI with CEO for asset purchase

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Mar 18, 2024 3:55pm

91 Views

Post# 35939023

RE:RepliCel Life signs LOI with CEO for asset purchase

Well Replicel shareholders, there you go !

The mystery is over: Takeover & Privatization. What do the shareholders get: an 8% Royalty of any future profits garnered from commercialization of any of the assets ("With the anticipated commercialization of the Assets not set until 2025-2027").

<< Previous

Bullboard Posts

Next >>

AI companies to invest in